Match the following neurocognitive or related psychiatric conditions with their most appropriate initial pharmacological management strategy or critical therapeutic constraint.
- Dementia with Lewy bodies (DLB) presenting with distressing visual hallucinationsHigh risk of severe sensitivity to typical antipsychotics; use pimavanserin or low-dose quetiapine if pharmacological management is mandatory.
- Behavioral variant frontotemporal dementia (bvFTD) presenting with severe impulsivityFirst-line pharmacological management targets behavioral symptoms (e.g., with SSRIs); cholinesterase inhibitors lack efficacy and may worsen agitation.
- Mild-to-moderate Alzheimer disease newly diagnosed in the outpatient settingFirst-line pharmacological management includes initiation of an acetylcholinesterase inhibitor (e.g., donepezil, rivastigmine).
- Major depressive disorder presenting with dementia-like cognitive impairment (pseudodementia)Primary treatment involves antidepressant therapy, which frequently reverses the associated cognitive deficits.
Cevap
Dementia with Lewy bodies matches with neuroleptic sensitivity; Behavioral variant frontotemporal dementia matches with SSRI use for behaviors and avoiding cholinesterase inhibitors; Alzheimer disease matches with initiating acetylcholinesterase inhibitors; Pseudodementia matches with antidepressant therapy reversing cognitive deficits.
Each condition pairs with a unique and essential pharmacological principle: DLB requires avoiding typical antipsychotics, bvFTD relies on SSRIs while avoiding AChE inhibitors, Alzheimer disease is primarily treated with AChE inhibitors, and pseudodementia cognitive deficits are reversible with antidepressants.
Adım Adım Çözüm
Anahtar Kavram
Pharmacological management and critical contraindications in major neurocognitive disorders